I agree the price may decline from initial euphoria that may come with the release of TLD, but still believe over a billion in market cap can be sustained until either a partnership hits, or approval.
I don't believe they want to go to approval without a partnership, but it's always a possibility, and if it should occur they'd actually be even more valuable, but they'd have to struggle through the financing needed to get the BLA done as well as getting DCVax-Direct into further trials. They will bring money in with conversion of warrants, etc. but in the long run some dilution will be needed if they don't partner. The big difference from today is they should be diluting from a price that's at least 5 times higher than we currently are.
Next year should be very interesting. Happy New Year's,
Gary
News 
Market Data 
Discover 
AI
